Showing results (321-330 of 374) with videos related to
Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.International Journal of Dermatology|May 19, 2023
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and managementRohan Mital, Tracey S Otto, Andrei Savu, et al.Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.JCSM Rapid Communications|September 13, 2021
Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humansAlyssa Marie M Castillo, Trang T Vu, Sophia G Liva, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.Frontiers in Immunology|April 16, 2026
Fc gamma receptor binding modulates IgG clearance in cancer cachexiaBryan C Remaily, Kyeongmin Kim, Justin Thomas, et al.Biomedicines|September 23, 2022
Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint InhibitorsJennifer K Matsui, Haley K Perlow, Rohit K Raj, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine NeoplasmsDwight H Owen, Brooke Benner, Lai Wei, et al.Pageof 38